ArticleJournal of the advanced practitioner in oncology2025
Patient and Advanced Practitioner Perspectives on Symptom Burden and Symptom Management in Indolent Systemic Mastocytosis.
Article in Journal of the advanced practitioner in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Symptom burden is the primary driver for patients with indolent systemic mastocytosis (ISM) to seek medical care, whether or not they are diagnosed. Purpose: This descriptive study aimed to describe the advanced practitioner (AP) and ISM patient perspective relative to the symptom burden of ISM, multidisciplinary diagnosis and management of ISM, barriers to symptom management, strategies for collaborative management of ISM, and communicative health literacy in patients with ISM. Methods: An ISM patient survey and AP survey were developed by an AP-led steering committee incorporating validated tools to measure symptom burden, symptom burden impact, barriers, and strategies for improving symptom burden. Surveys were embedded in Qualtrics and were deployed by Conexiant to a convenience sample of AP members of the Advanced Practitioner Society for Hematology/Oncology (APSHO), AP members of the American Initiative in Mast Cell Diseases, and patients affiliated with The Mast Cell Disease Society between December 22, 2024, and February 3, 2025. Findings: 50 APs and 53 ISM patients completed 100% of the questions on the corresponding surveys. The symptom burden described using the Indolent Systemic Mastocytosis Symptom Assessment Form (ISM-SAF) to identify the symptoms that are most common, most challenging, and have the greatest impact on quality of life aligns with published data for patients in this survey. Only 24% ( Conclusions: This is the first ISM symptom burden-focused survey to provide a direct comparison of patient responses to those of APs in hematology/oncology and allergy and immunology. Indolent systemic mastocytosis symptom burden measurement and symptom burden reduction remain challenging, with several barriers and gaps identified in this study. The APSHO Toolkit for Systemic Mastocytosis, developed in parallel to this study, provides an AP-focused resource for overcoming some of the barriers and gaps identified in this study.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.